06.02.25 -- Cell & Gene Therapy Manufacturing: Considerations For Early-Stage Companies

Don’t miss this compelling interview with Boro Dropulić, CEO of Caring Cross, on how the cell and gene therapy sector can turn scientific breakthroughs into global health solutions.

he effectiveness of cell-based therapies hinges on preserving cell viability, stability, and consistency. However, inconsistencies in cryopreservation methods have undermined therapeutic success.

Our findings provide critical insights into refining ASO extraction protocols, which can enhance the accuracy of downstream analyses and support further research into ASO-based therapeutics.

Optimize your biopharmaceutical technology transfer by prioritizing clear communication, thorough training, and strategic planning to ensure success.

Examine how a partnership leveraging expertise in production for high-quality CRISPR gRNAs as well as cGMP manufacturing is supporting the clinical translation of CRISPR genome editing technologies.

Explore insights into an AAV manufacturing platform designed to achieve short timelines and cost-effective scalability for producing clinical trial and commercial material in bioreactors up to 2000 L.

Increased investment in allogeneic therapies and process-level advancements to achieve commercial scale are paving the way for streamlined, standardized cell therapy development and manufacturing.

Discover a new potency bioassay using RT-qPCR to assess relative transcription activity, and learn more about the advantages and limitations of transcriptional assays versus reporter gene assays.

Learn the principles of commercialization readiness and guidance to address them in process development as well as the best time to implement automation and minimize commercialization risks.